Indication
Mayzent is indicated for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Mayzent is indicated for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features 1
Both newly diagnosed patients and patients switching from...
Kesimpta provides significant reduction in relapses of up to nearly 60% vs teriflunomide in RMS patients 1,2
ARR : Relative reduction in annualized relapses
Kesimpta shows a profound reduction...
A demonstrated safety and tolerability profile 2
Rate of infections between KESIMPTA ® and teriflunomide was comparable 1
1. Kesimpta...
KESIMPTA ® offers the flexibility of a self-administered B-cell therapy 1
After initial dosing, KESIMPTA ® 20 mg is administered (sc) once monthly 1 ...
B-cells play a central role in the pathogenesis of MS 2
KESIMPTA ® (ofatumumab) is a fully human anti...